Thrivent Financial for Lutherans Sells 41,997 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Thrivent Financial for Lutherans cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 332,662 shares of the medical research company’s stock after selling 41,997 shares during the quarter. Thrivent Financial for Lutherans owned 0.64% of Charles River Laboratories International worth $65,524,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its position in Charles River Laboratories International by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock valued at $346,821,000 after buying an additional 509,163 shares during the period. Epoch Investment Partners Inc. grew its position in Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock valued at $67,060,000 after buying an additional 238,766 shares during the period. Marshall Wace LLP grew its position in Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock valued at $170,615,000 after buying an additional 163,056 shares during the period. 1832 Asset Management L.P. bought a new stake in Charles River Laboratories International during the second quarter valued at approximately $33,053,000. Finally, Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% during the second quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after buying an additional 110,725 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 0.1 %

CRL stock opened at $187.50 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The stock has a market capitalization of $9.59 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 4.84 and a beta of 1.38. The firm’s fifty day simple moving average is $195.24 and its two-hundred day simple moving average is $206.89.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the previous year, the business posted $2.72 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current year.

Charles River Laboratories International declared that its board has approved a share buyback program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages recently issued reports on CRL. Bank of America lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, Baird R W lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $214.38.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).